Rapid Ebola Test Validated in Field Trials
|
By LabMedica International staff writers Posted on 15 Jul 2015 |
At present, diagnosis of Ebolavirus disease requires transport of venipuncture blood to field biocontainment laboratories for testing by real-time reverse transcription polymerase chain reaction (RT-PCR), resulting in delays that complicate patient care and infection control efforts.
However, RT-PCR is a slow and complex test that comes with attached risks for the health care workers responsible for the collection, transportation and testing of the blood. The complexity and slow turnaround for this diagnostic have been blamed for delaying success in containing the Ebola epidemic.
An international team led by those at the Boston Children's Hospital (MA. USA) performed a rapid diagnostic test on fingerstick blood samples from 106 individuals with suspected Ebolavirus disease presenting at two clinical centers in Sierra Leone during February 2015. They compared the point-of-care rapid diagnostic test results with clinical real-time RT-PCR results (RealStar Filovirus Screen RT-PCR kit 1·0; altona Diagnostics GmbH; Hamburg, Germany) for venipuncture plasma samples tested in a Public Health England field reference laboratory.
The team also performed the rapid diagnostic ReEBOV Antigen Rapid Test (Corgenix; Broomfield, CO, USA), on whole blood and real-time RT-PCR on plasma, on 284 specimens in the reference laboratory, which were submitted to the laboratory for testing from many clinical sites in Sierra Leone. In point-of-care testing, all 28 patients who tested positive for Ebolavirus disease by RT-PCR were also positive by fingerstick rapid diagnostic test and 71 of 77 patients who tested negative by RT-PCR were also negative by the rapid diagnostic test. In laboratory testing, all 45 specimens that tested positive by RT-PCR were also positive by the rapid diagnostic test, and 214 of 232 specimens that tested negative by RT-PCR were also negative by the rapid diagnostic test.
The authors concluded that the ReEBOV rapid diagnostic test had 100% sensitivity and 92% specificity in both point-of-care and reference laboratory testing in this population. With two independent readers, the test detected all patients who were positive for Ebolavirus by altona real-time RT-PCR; however, this benchmark itself had imperfect sensitivity. The study was published on June 26, 2015, in the journal the Lancet.
Related Links:
Boston Children's Hospital
altona Diagnostics GmbH
Corgenix
However, RT-PCR is a slow and complex test that comes with attached risks for the health care workers responsible for the collection, transportation and testing of the blood. The complexity and slow turnaround for this diagnostic have been blamed for delaying success in containing the Ebola epidemic.
An international team led by those at the Boston Children's Hospital (MA. USA) performed a rapid diagnostic test on fingerstick blood samples from 106 individuals with suspected Ebolavirus disease presenting at two clinical centers in Sierra Leone during February 2015. They compared the point-of-care rapid diagnostic test results with clinical real-time RT-PCR results (RealStar Filovirus Screen RT-PCR kit 1·0; altona Diagnostics GmbH; Hamburg, Germany) for venipuncture plasma samples tested in a Public Health England field reference laboratory.
The team also performed the rapid diagnostic ReEBOV Antigen Rapid Test (Corgenix; Broomfield, CO, USA), on whole blood and real-time RT-PCR on plasma, on 284 specimens in the reference laboratory, which were submitted to the laboratory for testing from many clinical sites in Sierra Leone. In point-of-care testing, all 28 patients who tested positive for Ebolavirus disease by RT-PCR were also positive by fingerstick rapid diagnostic test and 71 of 77 patients who tested negative by RT-PCR were also negative by the rapid diagnostic test. In laboratory testing, all 45 specimens that tested positive by RT-PCR were also positive by the rapid diagnostic test, and 214 of 232 specimens that tested negative by RT-PCR were also negative by the rapid diagnostic test.
The authors concluded that the ReEBOV rapid diagnostic test had 100% sensitivity and 92% specificity in both point-of-care and reference laboratory testing in this population. With two independent readers, the test detected all patients who were positive for Ebolavirus by altona real-time RT-PCR; however, this benchmark itself had imperfect sensitivity. The study was published on June 26, 2015, in the journal the Lancet.
Related Links:
Boston Children's Hospital
altona Diagnostics GmbH
Corgenix
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Channels
Clinical Chemistry
view channel
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
Many cancers deviate from the normal chromosome number, but the clinical impact of extreme chromosome loss remains unclear. This widespread genomic disruption is associated with aggressive disease and... Read more
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read more
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel









